Search

everythinglearnresearchcommunity

for

Search:↓

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

Nivolumab treatment led to hair regrowth in a man with metastatic melanoma and alopecia areata.

Donor lymphocyte infusions effectively treated leukemia relapse but caused vitiligo and alopecia areata.

The document concludes that treatment for cutaneous T-cell lymphoma should be customized to each patient's disease stage, balancing benefits and side effects, with no cure but many patients living long lives.

CD8+ T cells re-expressing CD45RA may predict treatment resistance in severe alopecia areata.

Co-trimoxazole may help treat autoimmune diseases.

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

Adalimumab helped control a child's severe eye disease when other treatments failed.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

Targeted radionuclide therapy shows promise for improving head and neck cancer treatment but needs more research.

Ruxolitinib effectively and safely regrows hair in alopecia patients.

Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.

Co-trimoxazole successfully treated a girl with multiple autoimmune symptoms.

Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.

Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.

A 16-year-old boy with Castleman's disease and lupus was successfully treated and showed no recurrence.

Trastuzumab may cause tufted hair folliculitis as a side effect.

Ritlecitinib is effective and safe for treating severe alopecia areata, showing significant hair regrowth and improved mental health.

The combination of mitoxantrone, etoposide, and prednisolone is effective for treating relapsed lymphoma with manageable side effects.

The combination therapy significantly improved Riehl’s melanosis in patients without serious side effects.

A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.

Skin-resident memory T cells may contribute to chronic alopecia areata and baricitinib could be a potential treatment.

Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.